#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=3 .
1-1	0-1	3	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Tailoring
2-1	4-13	Tailoring	_	_	_	_

#Text=Immunotherapy in Real-Life Clinical Practice
3-1	14-27	Immunotherapy	abstract[2]	new[2]	coref	4-20[14_2]
3-2	28-30	in	abstract[2]	new[2]	_	_
3-3	31-40	Real-Life	abstract[2]|abstract[4]	new[2]|new[4]	coref	7-15[45_4]
3-4	41-49	Clinical	abstract[2]|substance|abstract[4]	new[2]|new|new[4]	_	_
3-5	50-58	Practice	abstract[2]|abstract[4]	new[2]|new[4]	_	_

#Text=After the histology-agnostic approval of pembrolizumab in mismatch repair ( MMR)-deficient tumors , the predictive molecular pathology scenario in cancer immunotherapy changed radically .
4-1	59-64	After	_	_	_	_
4-2	65-68	the	abstract[5]	new[5]	_	_
4-3	69-87	histology-agnostic	abstract[5]	new[5]	_	_
4-4	88-96	approval	abstract[5]	new[5]	_	_
4-5	97-99	of	abstract[5]	new[5]	_	_
4-6	100-113	pembrolizumab	abstract[5]|substance	new[5]|new	_	_
4-7	114-116	in	abstract[5]	new[5]	_	_
4-8	117-125	mismatch	abstract[5]|object|abstract[8]	new[5]|new|new[8]	_	_
4-9	126-132	repair	abstract[5]|abstract[8]	new[5]|new[8]	_	_
4-10	133-134	(	_	_	_	_
4-11	135-149	MMR)-deficient	object[9]	new[9]	_	_
4-12	150-156	tumors	object[9]|object	new[9]|new	coref	12-6[64_0]
4-13	157-158	,	_	_	_	_
4-14	159-162	the	abstract[12]	new[12]	_	_
4-15	163-173	predictive	abstract[12]	new[12]	_	_
4-16	174-183	molecular	abstract[12]	new[12]	_	_
4-17	184-193	pathology	abstract|abstract[12]	new|new[12]	_	_
4-18	194-202	scenario	abstract[12]	new[12]	_	_
4-19	203-205	in	abstract[12]	new[12]	_	_
4-20	206-212	cancer	abstract[12]|abstract|abstract[14]	new[12]|new|giv[14]	coref|coref	6-11[28_14]|6-11[28_14]
4-21	213-226	immunotherapy	abstract[12]|abstract[14]	new[12]|giv[14]	_	_
4-22	227-234	changed	_	_	_	_
4-23	235-244	radically	_	_	_	_
4-24	245-246	.	_	_	_	_

#Text=For the first time in the history of medicine , a drug ( in this case , an immune-checkpoint inhibitor ) was approved based on a specific molecular feature of the neoplasm , irrespective of its anatomical site of origin .
5-1	247-250	For	_	_	_	_
5-2	251-254	the	time[15]	new[15]	coref	16-33[99_15]
5-3	255-260	first	time[15]	new[15]	_	_
5-4	261-265	time	time[15]	new[15]	_	_
5-5	266-268	in	time[15]	new[15]	_	_
5-6	269-272	the	time[15]|time[16]	new[15]|new[16]	_	_
5-7	273-280	history	time[15]|time[16]	new[15]|new[16]	_	_
5-8	281-283	of	time[15]|time[16]	new[15]|new[16]	_	_
5-9	284-292	medicine	time[15]|time[16]|abstract	new[15]|new[16]|new	_	_
5-10	293-294	,	_	_	_	_
5-11	295-296	a	substance[18]	new[18]	coref	21-20[134_18]
5-12	297-301	drug	substance[18]	new[18]	_	_
5-13	302-303	(	_	_	_	_
5-14	304-306	in	_	_	_	_
5-15	307-311	this	abstract[19]	new[19]	_	_
5-16	312-316	case	abstract[19]	new[19]	_	_
5-17	317-318	,	_	_	_	_
5-18	319-321	an	object[20]	new[20]	ana	5-36[0_20]
5-19	322-339	immune-checkpoint	object[20]	new[20]	_	_
5-20	340-349	inhibitor	object[20]	new[20]	_	_
5-21	350-351	)	_	_	_	_
5-22	352-355	was	_	_	_	_
5-23	356-364	approved	_	_	_	_
5-24	365-370	based	_	_	_	_
5-25	371-373	on	_	_	_	_
5-26	374-375	a	abstract[21]	new[21]	_	_
5-27	376-384	specific	abstract[21]	new[21]	_	_
5-28	385-394	molecular	abstract[21]	new[21]	_	_
5-29	395-402	feature	abstract[21]	new[21]	_	_
5-30	403-405	of	abstract[21]	new[21]	_	_
5-31	406-409	the	abstract[21]|object[22]	new[21]|new[22]	_	_
5-32	410-418	neoplasm	abstract[21]|object[22]	new[21]|new[22]	_	_
5-33	419-420	,	_	_	_	_
5-34	421-433	irrespective	_	_	_	_
5-35	434-436	of	_	_	_	_
5-36	437-440	its	object|place[24]	giv|new[24]	_	_
5-37	441-451	anatomical	place[24]	new[24]	_	_
5-38	452-456	site	place[24]	new[24]	_	_
5-39	457-459	of	place[24]	new[24]	_	_
5-40	460-466	origin	place[24]|abstract	new[24]|new	_	_
5-41	467-468	.	_	_	_	_

#Text=A multitude of different tools has been proposed to inform immunotherapy , including morphology , immunohistochemistry ( IHC ) , polymerase chain reaction ( PCR)-based techniques and next-generation technology assays , such as next-generation sequencing ( NGS ) or multiplex barcode technology ( e. g. , NanoString ) .
6-1	469-470	A	abstract[26]	new[26]	_	_
6-2	471-480	multitude	abstract[26]	new[26]	_	_
6-3	481-483	of	abstract[26]	new[26]	_	_
6-4	484-493	different	abstract[26]|object[27]	new[26]|new[27]	coref	7-4[42_27]
6-5	494-499	tools	abstract[26]|object[27]	new[26]|new[27]	_	_
6-6	500-503	has	_	_	_	_
6-7	504-508	been	_	_	_	_
6-8	509-517	proposed	_	_	_	_
6-9	518-520	to	_	_	_	_
6-10	521-527	inform	_	_	_	_
6-11	528-541	immunotherapy	abstract[28]	giv[28]	coref	10-8[0_28]
6-12	542-543	,	abstract[28]	giv[28]	_	_
6-13	544-553	including	abstract[28]	giv[28]	_	_
6-14	554-564	morphology	abstract[28]|abstract	giv[28]|new	_	_
6-15	565-566	,	abstract[28]	giv[28]	_	_
6-16	567-587	immunohistochemistry	abstract[28]|abstract	giv[28]|new	appos	6-18
6-17	588-589	(	abstract[28]	giv[28]	_	_
6-18	590-593	IHC	abstract[28]|abstract	giv[28]|giv	coref	19-4[116_0]
6-19	594-595	)	abstract[28]	giv[28]	_	_
6-20	596-597	,	abstract[28]	giv[28]	_	_
6-21	598-608	polymerase	abstract[28]|abstract[32]	giv[28]|new[32]	appos	6-25[33_32]
6-22	609-614	chain	abstract[28]|abstract[32]	giv[28]|new[32]	_	_
6-23	615-623	reaction	abstract[28]|abstract[32]	giv[28]|new[32]	_	_
6-24	624-625	(	abstract[28]	giv[28]	_	_
6-25	626-636	PCR)-based	abstract[28]|abstract[33]	giv[28]|giv[33]	coref	21-3[129_33]
6-26	637-647	techniques	abstract[28]|abstract[33]	giv[28]|giv[33]	_	_
6-27	648-651	and	abstract[28]|abstract[33]	giv[28]|giv[33]	_	_
6-28	652-667	next-generation	abstract[28]|abstract[33]	giv[28]|giv[33]	_	_
6-29	668-678	technology	abstract[28]|abstract[33]|abstract	giv[28]|giv[33]|new	coref	6-40[40_0]
6-30	679-685	assays	abstract[28]|abstract[33]	giv[28]|giv[33]	_	_
6-31	686-687	,	abstract[28]|abstract[33]	giv[28]|giv[33]	_	_
6-32	688-692	such	abstract[28]|abstract[33]	giv[28]|giv[33]	_	_
6-33	693-695	as	abstract[28]|abstract[33]	giv[28]|giv[33]	_	_
6-34	696-711	next-generation	abstract[28]|abstract[33]|abstract|abstract[36]	giv[28]|giv[33]|new|new[36]	appos|appos	6-37[0_36]|6-37[0_36]
6-35	712-722	sequencing	abstract[28]|abstract[33]|abstract[36]	giv[28]|giv[33]|new[36]	_	_
6-36	723-724	(	abstract[28]	giv[28]	_	_
6-37	725-728	NGS	abstract[28]|abstract	giv[28]|giv	coref	13-23
6-38	729-730	)	abstract[28]	giv[28]	_	_
6-39	731-733	or	abstract[28]	giv[28]	_	_
6-40	734-743	multiplex	abstract[28]|place|abstract[40]	giv[28]|new|giv[40]	_	_
6-41	744-751	barcode	abstract[28]|abstract|abstract[40]	giv[28]|new|giv[40]	_	_
6-42	752-762	technology	abstract[28]|abstract[40]	giv[28]|giv[40]	_	_
6-43	763-764	(	_	_	_	_
6-44	765-767	e.	_	_	_	_
6-45	768-770	g.	_	_	_	_
6-46	771-772	,	_	_	_	_
6-47	773-783	NanoString	object	new	_	_
6-48	784-785	)	_	_	_	_
6-49	786-787	.	_	_	_	_

#Text=However , not all the available tools are validated for patients ’ selection in clinical practice , as shown in
7-1	788-795	However	_	_	_	_
7-2	796-797	,	_	_	_	_
7-3	798-801	not	_	_	_	_
7-4	802-805	all	object[42]	giv[42]	_	_
7-5	806-809	the	object[42]	giv[42]	_	_
7-6	810-819	available	object[42]	giv[42]	_	_
7-7	820-825	tools	object[42]	giv[42]	_	_
7-8	826-829	are	_	_	_	_
7-9	830-839	validated	_	_	_	_
7-10	840-843	for	_	_	_	_
7-11	844-852	patients	person[43]|event[44]	new[43]|new[44]	coref|coref|coref|coref	10-6[0_43]|25-6[148_44]|10-6[0_43]|25-6[148_44]
7-12	853-854	’	person[43]|event[44]	new[43]|new[44]	_	_
7-13	855-864	selection	event[44]	new[44]	_	_
7-14	865-867	in	event[44]	new[44]	_	_
7-15	868-876	clinical	event[44]|abstract[45]	new[44]|giv[45]	coref	27-7[166_45]
7-16	877-885	practice	event[44]|abstract[45]	new[44]|giv[45]	_	_
7-17	886-887	,	_	_	_	_
7-18	888-890	as	_	_	_	_
7-19	891-896	shown	_	_	_	_
7-20	897-899	in	_	_	_	_

#Text=Figure 1
8-1	900-906	Figure	object[46]	new[46]	_	_
8-2	907-908	1	object[46]	new[46]	_	_

#Text=.
9-1	909-910	.	_	_	_	_

#Text=Among new biomarkers to select patients for immunotherapy , the tumor mutational burden ( TMB ) has been shown a strong correlation with the response to some compounds .
10-1	911-916	Among	_	_	_	_
10-2	917-920	new	abstract[47]	new[47]	_	_
10-3	921-931	biomarkers	abstract[47]	new[47]	_	_
10-4	932-934	to	_	_	_	_
10-5	935-941	select	_	_	_	_
10-6	942-950	patients	person	giv	_	_
10-7	951-954	for	_	_	_	_
10-8	955-968	immunotherapy	abstract	giv	coref	25-11
10-9	969-970	,	_	_	_	_
10-10	971-974	the	abstract[51]	new[51]	appos	10-15[0_51]
10-11	975-980	tumor	abstract|abstract[51]	new|new[51]	coref	11-17
10-12	981-991	mutational	abstract[51]	new[51]	_	_
10-13	992-998	burden	abstract[51]	new[51]	_	_
10-14	999-1000	(	_	_	_	_
10-15	1001-1004	TMB	abstract	giv	coref	11-1
10-16	1005-1006	)	_	_	_	_
10-17	1007-1010	has	_	_	_	_
10-18	1011-1015	been	_	_	_	_
10-19	1016-1021	shown	_	_	_	_
10-20	1022-1023	a	abstract[53]	new[53]	_	_
10-21	1024-1030	strong	abstract[53]	new[53]	_	_
10-22	1031-1042	correlation	abstract[53]	new[53]	_	_
10-23	1043-1047	with	abstract[53]	new[53]	_	_
10-24	1048-1051	the	abstract[53]|abstract[54]	new[53]|new[54]	coref	12-20[67_54]
10-25	1052-1060	response	abstract[53]|abstract[54]	new[53]|new[54]	_	_
10-26	1061-1063	to	abstract[53]|abstract[54]	new[53]|new[54]	_	_
10-27	1064-1068	some	abstract[53]|abstract[54]|substance[55]	new[53]|new[54]|new[55]	_	_
10-28	1069-1078	compounds	abstract[53]|abstract[54]|substance[55]	new[53]|new[54]|new[55]	_	_
10-29	1079-1080	.	_	_	_	_

#Text=TMB is defined by the total number of somatic nonsynonymous mutations per coding area of the tumor DNA .
11-1	1081-1084	TMB	abstract	giv	coref	12-8[65_0]
11-2	1085-1087	is	_	_	_	_
11-3	1088-1095	defined	_	_	_	_
11-4	1096-1098	by	_	_	_	_
11-5	1099-1102	the	quantity[57]	new[57]	_	_
11-6	1103-1108	total	quantity[57]	new[57]	_	_
11-7	1109-1115	number	quantity[57]	new[57]	_	_
11-8	1116-1118	of	quantity[57]	new[57]	_	_
11-9	1119-1126	somatic	quantity[57]|abstract[58]	new[57]|new[58]	_	_
11-10	1127-1140	nonsynonymous	quantity[57]|abstract[58]	new[57]|new[58]	_	_
11-11	1141-1150	mutations	quantity[57]|abstract[58]	new[57]|new[58]	_	_
11-12	1151-1154	per	quantity[57]|abstract[58]	new[57]|new[58]	_	_
11-13	1155-1161	coding	quantity[57]|abstract[58]|abstract|place[60]	new[57]|new[58]|new|new[60]	_	_
11-14	1162-1166	area	quantity[57]|abstract[58]|place[60]	new[57]|new[58]|new[60]	_	_
11-15	1167-1169	of	quantity[57]|abstract[58]|place[60]	new[57]|new[58]|new[60]	_	_
11-16	1170-1173	the	quantity[57]|abstract[58]|place[60]|abstract[62]	new[57]|new[58]|new[60]|new[62]	ana	12-1[0_62]
11-17	1174-1179	tumor	quantity[57]|abstract[58]|place[60]|abstract|abstract[62]	new[57]|new[58]|new[60]|giv|new[62]	coref	16-23
11-18	1180-1183	DNA	quantity[57]|abstract[58]|place[60]|abstract[62]	new[57]|new[58]|new[60]|new[62]	_	_
11-19	1184-1185	.	_	_	_	_

#Text=It has been hypothesized that tumors with a higher TMB are more likely to express neoantigens and to induce a more robust immune response in the presence of immune checkpoint inhibitors .
12-1	1186-1188	It	abstract	giv	_	_
12-2	1189-1192	has	_	_	_	_
12-3	1193-1197	been	_	_	_	_
12-4	1198-1210	hypothesized	_	_	_	_
12-5	1211-1215	that	_	_	_	_
12-6	1216-1222	tumors	object[64]	giv[64]	coref	20-4[122_64]
12-7	1223-1227	with	object[64]	giv[64]	_	_
12-8	1228-1229	a	object[64]|abstract[65]	giv[64]|giv[65]	coref	13-4[0_65]
12-9	1230-1236	higher	object[64]|abstract[65]	giv[64]|giv[65]	_	_
12-10	1237-1240	TMB	object[64]|abstract[65]	giv[64]|giv[65]	_	_
12-11	1241-1244	are	_	_	_	_
12-12	1245-1249	more	_	_	_	_
12-13	1250-1256	likely	_	_	_	_
12-14	1257-1259	to	_	_	_	_
12-15	1260-1267	express	_	_	_	_
12-16	1268-1279	neoantigens	abstract	new	_	_
12-17	1280-1283	and	_	_	_	_
12-18	1284-1286	to	_	_	_	_
12-19	1287-1293	induce	_	_	_	_
12-20	1294-1295	a	abstract[67]	giv[67]	coref	32-13[204_67]
12-21	1296-1300	more	abstract[67]	giv[67]	_	_
12-22	1301-1307	robust	abstract[67]	giv[67]	_	_
12-23	1308-1314	immune	abstract[67]	giv[67]	_	_
12-24	1315-1323	response	abstract[67]	giv[67]	_	_
12-25	1324-1326	in	_	_	_	_
12-26	1327-1330	the	abstract[68]	new[68]	_	_
12-27	1331-1339	presence	abstract[68]	new[68]	_	_
12-28	1340-1342	of	abstract[68]	new[68]	_	_
12-29	1343-1349	immune	abstract[68]|abstract|abstract[71]	new[68]|new|new[71]	_	_
12-30	1350-1360	checkpoint	abstract[68]|place|abstract[71]	new[68]|new|new[71]	_	_
12-31	1361-1371	inhibitors	abstract[68]|abstract[71]	new[68]|new[71]	_	_
12-32	1372-1373	.	_	_	_	_

#Text=Regrettably , the TMB analysis is considered expensive , time-consuming , and deceptive if the analyses are carried out with an unsuitable NGS panel .
13-1	1374-1385	Regrettably	_	_	_	_
13-2	1386-1387	,	_	_	_	_
13-3	1388-1391	the	abstract[73]	new[73]	coref	14-5[79_73]
13-4	1392-1395	TMB	abstract|abstract[73]	giv|new[73]	coref	14-5
13-5	1396-1404	analysis	abstract[73]	new[73]	_	_
13-6	1405-1407	is	_	_	_	_
13-7	1408-1418	considered	_	_	_	_
13-8	1419-1428	expensive	_	_	_	_
13-9	1429-1430	,	_	_	_	_
13-10	1431-1445	time-consuming	_	_	_	_
13-11	1446-1447	,	_	_	_	_
13-12	1448-1451	and	_	_	_	_
13-13	1452-1461	deceptive	_	_	_	_
13-14	1462-1464	if	_	_	_	_
13-15	1465-1468	the	abstract[74]	new[74]	coref	20-21[127_74]
13-16	1469-1477	analyses	abstract[74]	new[74]	_	_
13-17	1478-1481	are	_	_	_	_
13-18	1482-1489	carried	_	_	_	_
13-19	1490-1493	out	_	_	_	_
13-20	1494-1498	with	_	_	_	_
13-21	1499-1501	an	object[76]	new[76]	_	_
13-22	1502-1512	unsuitable	object[76]	new[76]	_	_
13-23	1513-1516	NGS	abstract|object[76]	giv|new[76]	coref	15-13[88_0]
13-24	1517-1522	panel	object[76]	new[76]	_	_
13-25	1523-1524	.	_	_	_	_

#Text=Another important facet in TMB analysis is represented by the lack of widely adopted guidelines and recommendations for its assessment and reporting .
14-1	1525-1532	Another	abstract[77]	new[77]	_	_
14-2	1533-1542	important	abstract[77]	new[77]	_	_
14-3	1543-1548	facet	abstract[77]	new[77]	_	_
14-4	1549-1551	in	abstract[77]	new[77]	_	_
14-5	1552-1555	TMB	abstract[77]|abstract|abstract[79]	new[77]|giv|giv[79]	coref|coref|coref|coref	15-3|18-3[105_79]|15-3|18-3[105_79]
14-6	1556-1564	analysis	abstract[77]|abstract[79]	new[77]|giv[79]	_	_
14-7	1565-1567	is	_	_	_	_
14-8	1568-1579	represented	_	_	_	_
14-9	1580-1582	by	_	_	_	_
14-10	1583-1586	the	abstract[80]	new[80]	_	_
14-11	1587-1591	lack	abstract[80]	new[80]	_	_
14-12	1592-1594	of	abstract[80]	new[80]	_	_
14-13	1595-1601	widely	abstract[80]|abstract[81]	new[80]|new[81]	coref	24-17[0_81]
14-14	1602-1609	adopted	abstract[80]|abstract[81]	new[80]|new[81]	_	_
14-15	1610-1620	guidelines	abstract[80]|abstract[81]	new[80]|new[81]	_	_
14-16	1621-1624	and	abstract[80]	new[80]	_	_
14-17	1625-1640	recommendations	abstract[80]|abstract[82]	new[80]|new[82]	_	_
14-18	1641-1644	for	abstract[80]|abstract[82]	new[80]|new[82]	_	_
14-19	1645-1648	its	abstract[80]|abstract[82]|abstract[83]	new[80]|new[82]|new[83]	_	_
14-20	1649-1659	assessment	abstract[80]|abstract[82]|abstract[83]	new[80]|new[82]|new[83]	_	_
14-21	1660-1663	and	abstract[80]|abstract[82]	new[80]|new[82]	_	_
14-22	1664-1673	reporting	abstract[80]|abstract[82]|abstract	new[80]|new[82]|new	_	_
14-23	1674-1675	.	_	_	_	_

#Text=Initially , TMB was determined using wide approaches ( e. g. , whole exome sequencing ) , but more focused gene panels are currently being explored .
15-1	1676-1685	Initially	_	_	_	_
15-2	1686-1687	,	_	_	_	_
15-3	1688-1691	TMB	abstract	giv	coref	16-9
15-4	1692-1695	was	_	_	_	_
15-5	1696-1706	determined	_	_	_	_
15-6	1707-1712	using	_	_	_	_
15-7	1713-1717	wide	abstract[86]	new[86]	_	_
15-8	1718-1728	approaches	abstract[86]	new[86]	_	_
15-9	1729-1730	(	_	_	_	_
15-10	1731-1733	e.	_	_	_	_
15-11	1734-1736	g.	_	_	_	_
15-12	1737-1738	,	_	_	_	_
15-13	1739-1744	whole	abstract[88]	giv[88]	_	_
15-14	1745-1750	exome	abstract|abstract[88]	new|giv[88]	_	_
15-15	1751-1761	sequencing	abstract[88]	giv[88]	_	_
15-16	1762-1763	)	_	_	_	_
15-17	1764-1765	,	_	_	_	_
15-18	1766-1769	but	_	_	_	_
15-19	1770-1774	more	_	_	_	_
15-20	1775-1782	focused	_	_	_	_
15-21	1783-1787	gene	abstract|person[90]	new|new[90]	coref|coref	17-7[103_90]|17-7[103_90]
15-22	1788-1794	panels	person[90]	new[90]	_	_
15-23	1795-1798	are	_	_	_	_
15-24	1799-1808	currently	_	_	_	_
15-25	1809-1814	being	_	_	_	_
15-26	1815-1823	explored	_	_	_	_
15-27	1824-1825	.	_	_	_	_

#Text=In addition , there are several indications that TMB is not a universal biomarker , as its value varies not only across tumor types but also across different genomic regions and during the time .
16-1	1826-1828	In	_	_	_	_
16-2	1829-1837	addition	_	_	_	_
16-3	1838-1839	,	_	_	_	_
16-4	1840-1845	there	_	_	_	_
16-5	1846-1849	are	_	_	_	_
16-6	1850-1857	several	abstract[91]	new[91]	_	_
16-7	1858-1869	indications	abstract[91]	new[91]	_	_
16-8	1870-1874	that	_	_	_	_
16-9	1875-1878	TMB	abstract	giv	coref	17-8
16-10	1879-1881	is	_	_	_	_
16-11	1882-1885	not	_	_	_	_
16-12	1886-1887	a	abstract[93]	new[93]	ana	16-17[0_93]
16-13	1888-1897	universal	abstract[93]	new[93]	_	_
16-14	1898-1907	biomarker	abstract[93]	new[93]	_	_
16-15	1908-1909	,	_	_	_	_
16-16	1910-1912	as	_	_	_	_
16-17	1913-1916	its	abstract|abstract[95]	giv|new[95]	coref|coref	31-7[197_95]|31-7[197_95]
16-18	1917-1922	value	abstract[95]	new[95]	_	_
16-19	1923-1929	varies	_	_	_	_
16-20	1930-1933	not	_	_	_	_
16-21	1934-1938	only	place[97]	new[97]	coref	22-15[141_97]
16-22	1939-1945	across	place[97]	new[97]	_	_
16-23	1946-1951	tumor	abstract|place[97]	giv|new[97]	coref	22-16
16-24	1952-1957	types	place[97]	new[97]	_	_
16-25	1958-1961	but	_	_	_	_
16-26	1962-1966	also	_	_	_	_
16-27	1967-1973	across	_	_	_	_
16-28	1974-1983	different	abstract[98]	new[98]	_	_
16-29	1984-1991	genomic	abstract[98]	new[98]	_	_
16-30	1992-1999	regions	abstract[98]	new[98]	_	_
16-31	2000-2003	and	_	_	_	_
16-32	2004-2010	during	_	_	_	_
16-33	2011-2014	the	time[99]	giv[99]	_	_
16-34	2015-2019	time	time[99]	giv[99]	_	_
16-35	2020-2021	.	_	_	_	_

#Text=This notion highlights the need for disease-specific TMB panels and thresholds .
17-1	2022-2026	This	abstract[100]	new[100]	_	_
17-2	2027-2033	notion	abstract[100]	new[100]	_	_
17-3	2034-2044	highlights	_	_	_	_
17-4	2045-2048	the	abstract[101]	new[101]	_	_
17-5	2049-2053	need	abstract[101]	new[101]	_	_
17-6	2054-2057	for	abstract[101]	new[101]	_	_
17-7	2058-2074	disease-specific	abstract[101]|person[103]	new[101]|giv[103]	_	_
17-8	2075-2078	TMB	abstract[101]|abstract|person[103]	new[101]|giv|giv[103]	_	_
17-9	2079-2085	panels	abstract[101]|person[103]	new[101]|giv[103]	_	_
17-10	2086-2089	and	abstract[101]|person[103]	new[101]|giv[103]	_	_
17-11	2090-2100	thresholds	abstract[101]|person[103]|abstract	new[101]|giv[103]|new	_	_
17-12	2101-2102	.	_	_	_	_

#Text=Likewise , the analysis of the MMR status is troubled by the vastity of the existing diagnostic methods in the substantial absence of companion diagnostic ( CD ) tests .
18-1	2103-2111	Likewise	_	_	_	_
18-2	2112-2113	,	_	_	_	_
18-3	2114-2117	the	abstract[105]	giv[105]	coref	25-15[151_105]
18-4	2118-2126	analysis	abstract[105]	giv[105]	_	_
18-5	2127-2129	of	abstract[105]	giv[105]	_	_
18-6	2130-2133	the	abstract[105]|abstract[107]	giv[105]|new[107]	_	_
18-7	2134-2137	MMR	abstract[105]|abstract|abstract[107]	giv[105]|new|new[107]	coref	19-4
18-8	2138-2144	status	abstract[105]|abstract[107]	giv[105]|new[107]	_	_
18-9	2145-2147	is	_	_	_	_
18-10	2148-2156	troubled	_	_	_	_
18-11	2157-2159	by	_	_	_	_
18-12	2160-2163	the	abstract[108]	new[108]	_	_
18-13	2164-2171	vastity	abstract[108]	new[108]	_	_
18-14	2172-2174	of	abstract[108]	new[108]	_	_
18-15	2175-2178	the	abstract[108]|abstract[109]	new[108]|new[109]	coref	24-14[144_109]
18-16	2179-2187	existing	abstract[108]|abstract[109]	new[108]|new[109]	_	_
18-17	2188-2198	diagnostic	abstract[108]|abstract[109]	new[108]|new[109]	_	_
18-18	2199-2206	methods	abstract[108]|abstract[109]	new[108]|new[109]	_	_
18-19	2207-2209	in	abstract[108]|abstract[109]	new[108]|new[109]	_	_
18-20	2210-2213	the	abstract[108]|abstract[109]|abstract[110]	new[108]|new[109]|new[110]	_	_
18-21	2214-2225	substantial	abstract[108]|abstract[109]|abstract[110]	new[108]|new[109]|new[110]	_	_
18-22	2226-2233	absence	abstract[108]|abstract[109]|abstract[110]	new[108]|new[109]|new[110]	_	_
18-23	2234-2236	of	abstract[108]|abstract[109]|abstract[110]	new[108]|new[109]|new[110]	_	_
18-24	2237-2246	companion	abstract[108]|abstract[109]|abstract[110]|abstract[111]	new[108]|new[109]|new[110]|new[111]	appos	18-27[0_111]
18-25	2247-2257	diagnostic	abstract[108]|abstract[109]|abstract[110]|abstract[111]	new[108]|new[109]|new[110]|new[111]	_	_
18-26	2258-2259	(	abstract[108]|abstract[109]|abstract[110]	new[108]|new[109]|new[110]	_	_
18-27	2260-2262	CD	abstract[108]|abstract[109]|abstract[110]|abstract	new[108]|new[109]|new[110]|giv	_	_
18-28	2263-2264	)	abstract[108]|abstract[109]|abstract[110]	new[108]|new[109]|new[110]	_	_
18-29	2265-2270	tests	abstract[108]|abstract[109]|abstract[110]|abstract	new[108]|new[109]|new[110]|new	_	_
18-30	2271-2272	.	_	_	_	_

#Text=In general , MMR IHC is mirrored by microsatellite instability ( MSI ) in endometrial and colorectal cancers .
19-1	2273-2275	In	_	_	_	_
19-2	2276-2283	general	person	new	_	_
19-3	2284-2285	,	_	_	_	_
19-4	2286-2289	MMR	abstract|abstract[116]	giv|giv[116]	_	_
19-5	2290-2293	IHC	abstract[116]	giv[116]	_	_
19-6	2294-2296	is	_	_	_	_
19-7	2297-2305	mirrored	_	_	_	_
19-8	2306-2308	by	_	_	_	_
19-9	2309-2323	microsatellite	abstract[117]	new[117]	appos	19-12[0_117]
19-10	2324-2335	instability	abstract[117]	new[117]	_	_
19-11	2336-2337	(	_	_	_	_
19-12	2338-2341	MSI	abstract	giv	coref	20-8
19-13	2342-2343	)	_	_	_	_
19-14	2344-2346	in	_	_	_	_
19-15	2347-2358	endometrial	place	new	_	_
19-16	2359-2362	and	_	_	_	_
19-17	2363-2373	colorectal	abstract[120]	new[120]	_	_
19-18	2374-2381	cancers	abstract[120]	new[120]	_	_
19-19	2382-2383	.	_	_	_	_

#Text=However , not all MMR-deficient tumors show MSI ( e. g. , breast cancers ) , questioning the interchangeability of these analyses as pan-cancer predictive tests .
20-1	2384-2391	However	_	_	_	_
20-2	2392-2393	,	_	_	_	_
20-3	2394-2397	not	_	_	_	_
20-4	2398-2401	all	object[122]	giv[122]	coref	21-25[135_122]
20-5	2402-2415	MMR-deficient	object|object[122]	new|giv[122]	_	_
20-6	2416-2422	tumors	object[122]	giv[122]	_	_
20-7	2423-2427	show	_	_	_	_
20-8	2428-2431	MSI	abstract	giv	appos	20-10[124_0]
20-9	2432-2433	(	_	_	_	_
20-10	2434-2436	e.	abstract[124]	giv[124]	_	_
20-11	2437-2439	g.	abstract[124]	giv[124]	_	_
20-12	2440-2441	,	_	_	_	_
20-13	2442-2448	breast	place	new	_	_
20-14	2449-2456	cancers	_	_	_	_
20-15	2457-2458	)	_	_	_	_
20-16	2459-2460	,	_	_	_	_
20-17	2461-2472	questioning	_	_	_	_
20-18	2473-2476	the	abstract[126]	new[126]	_	_
20-19	2477-2495	interchangeability	abstract[126]	new[126]	_	_
20-20	2496-2498	of	abstract[126]	new[126]	_	_
20-21	2499-2504	these	abstract[126]|abstract[127]	new[126]|giv[127]	_	_
20-22	2505-2513	analyses	abstract[126]|abstract[127]	new[126]|giv[127]	_	_
20-23	2514-2516	as	abstract[126]|abstract[127]	new[126]|giv[127]	_	_
20-24	2517-2527	pan-cancer	abstract[126]|abstract[127]	new[126]|giv[127]	_	_
20-25	2528-2538	predictive	abstract[126]|abstract[127]	new[126]|giv[127]	_	_
20-26	2539-2544	tests	abstract[126]|abstract[127]	new[126]|giv[127]	_	_
20-27	2545-2546	.	_	_	_	_

#Text=Hence , MMR/MSI assays have been originally developed by geneticists to identify Lynch syndrome families and not for choosing the optimal drug to treat acquired tumors .
21-1	2547-2552	Hence	_	_	_	_
21-2	2553-2554	,	_	_	_	_
21-3	2555-2562	MMR/MSI	organization|abstract[129]	new|giv[129]	coref|coref	24-11[0_129]|24-11[0_129]
21-4	2563-2569	assays	abstract[129]	giv[129]	_	_
21-5	2570-2574	have	_	_	_	_
21-6	2575-2579	been	_	_	_	_
21-7	2580-2590	originally	_	_	_	_
21-8	2591-2600	developed	_	_	_	_
21-9	2601-2603	by	_	_	_	_
21-10	2604-2615	geneticists	abstract	new	_	_
21-11	2616-2618	to	_	_	_	_
21-12	2619-2627	identify	_	_	_	_
21-13	2628-2633	Lynch	person|abstract[133]	new|new[133]	_	_
21-14	2634-2642	syndrome	event|abstract[133]	new|new[133]	_	_
21-15	2643-2651	families	abstract[133]	new[133]	_	_
21-16	2652-2655	and	_	_	_	_
21-17	2656-2659	not	_	_	_	_
21-18	2660-2663	for	_	_	_	_
21-19	2664-2672	choosing	_	_	_	_
21-20	2673-2676	the	substance[134]	giv[134]	_	_
21-21	2677-2684	optimal	substance[134]	giv[134]	_	_
21-22	2685-2689	drug	substance[134]	giv[134]	_	_
21-23	2690-2692	to	_	_	_	_
21-24	2693-2698	treat	_	_	_	_
21-25	2699-2707	acquired	object[135]	giv[135]	_	_
21-26	2708-2714	tumors	object[135]	giv[135]	_	_
21-27	2715-2716	.	_	_	_	_

#Text=Given the wide heterogeneity in the repertoire of molecular alterations in immune-related genes across different tumor types (
22-1	2717-2722	Given	_	_	_	_
22-2	2723-2726	the	abstract[136]	new[136]	_	_
22-3	2727-2731	wide	abstract[136]	new[136]	_	_
22-4	2732-2745	heterogeneity	abstract[136]	new[136]	_	_
22-5	2746-2748	in	abstract[136]	new[136]	_	_
22-6	2749-2752	the	abstract[136]|abstract[137]	new[136]|new[137]	coref	34-26[221_137]
22-7	2753-2763	repertoire	abstract[136]|abstract[137]	new[136]|new[137]	_	_
22-8	2764-2766	of	abstract[136]|abstract[137]	new[136]|new[137]	_	_
22-9	2767-2776	molecular	abstract[136]|abstract[137]|abstract[138]	new[136]|new[137]|new[138]	_	_
22-10	2777-2788	alterations	abstract[136]|abstract[137]|abstract[138]	new[136]|new[137]|new[138]	_	_
22-11	2789-2791	in	abstract[136]|abstract[137]|abstract[138]	new[136]|new[137]|new[138]	_	_
22-12	2792-2806	immune-related	abstract[136]|abstract[137]|abstract[138]|abstract[139]	new[136]|new[137]|new[138]|new[139]	_	_
22-13	2807-2812	genes	abstract[136]|abstract[137]|abstract[138]|abstract[139]	new[136]|new[137]|new[138]|new[139]	_	_
22-14	2813-2819	across	abstract[136]|abstract[137]|abstract[138]|abstract[139]	new[136]|new[137]|new[138]|new[139]	_	_
22-15	2820-2829	different	abstract[136]|abstract[137]|abstract[138]|abstract[139]|place[141]	new[136]|new[137]|new[138]|new[139]|giv[141]	coref	28-22[176_141]
22-16	2830-2835	tumor	abstract[136]|abstract[137]|abstract[138]|abstract[139]|abstract|place[141]	new[136]|new[137]|new[138]|new[139]|giv|giv[141]	coref	28-23
22-17	2836-2841	types	abstract[136]|abstract[137]|abstract[138]|abstract[139]|place[141]	new[136]|new[137]|new[138]|new[139]|giv[141]	_	_
22-18	2842-2843	(	_	_	_	_

#Text=Figure 2
23-1	2844-2850	Figure	abstract[142]	new[142]	_	_
23-2	2851-2852	2	abstract[142]	new[142]	_	_

#Text=) , novel , efficient , reproducible , and reliable techniques coupled with tumor-specific methods and guidelines are needed .
24-1	2853-2854	)	_	_	_	_
24-2	2855-2856	,	_	_	_	_
24-3	2857-2862	novel	_	_	_	_
24-4	2863-2864	,	_	_	_	_
24-5	2865-2874	efficient	_	_	_	_
24-6	2875-2876	,	_	_	_	_
24-7	2877-2889	reproducible	_	_	_	_
24-8	2890-2891	,	_	_	_	_
24-9	2892-2895	and	_	_	_	_
24-10	2896-2904	reliable	_	_	_	_
24-11	2905-2915	techniques	abstract	giv	_	_
24-12	2916-2923	coupled	_	_	_	_
24-13	2924-2928	with	_	_	_	_
24-14	2929-2943	tumor-specific	abstract[144]	giv[144]	_	_
24-15	2944-2951	methods	abstract[144]	giv[144]	_	_
24-16	2952-2955	and	abstract[144]	giv[144]	_	_
24-17	2956-2966	guidelines	abstract[144]|abstract	giv[144]|giv	coref	28-13[174_0]
24-18	2967-2970	are	_	_	_	_
24-19	2971-2977	needed	_	_	_	_
24-20	2978-2979	.	_	_	_	_

#Text=Another important issue related to the patient ’s selection for immunotherapy is represented by the PD-L1 analysis by IHC .
25-1	2980-2987	Another	abstract[146]	new[146]	_	_
25-2	2988-2997	important	abstract[146]	new[146]	_	_
25-3	2998-3003	issue	abstract[146]	new[146]	_	_
25-4	3004-3011	related	_	_	_	_
25-5	3012-3014	to	_	_	_	_
25-6	3015-3018	the	event[148]	giv[148]	_	_
25-7	3019-3026	patient	person[147]|event[148]	new[147]|giv[148]	_	_
25-8	3027-3029	’s	person[147]|event[148]	new[147]|giv[148]	_	_
25-9	3030-3039	selection	event[148]	giv[148]	_	_
25-10	3040-3043	for	event[148]	giv[148]	_	_
25-11	3044-3057	immunotherapy	event[148]|abstract	giv[148]|giv	_	_
25-12	3058-3060	is	_	_	_	_
25-13	3061-3072	represented	_	_	_	_
25-14	3073-3075	by	_	_	_	_
25-15	3076-3079	the	abstract[151]	giv[151]	_	_
25-16	3080-3085	PD-L1	abstract|abstract[151]	new|giv[151]	coref	26-20
25-17	3086-3094	analysis	abstract[151]	giv[151]	_	_
25-18	3095-3097	by	abstract[151]	giv[151]	_	_
25-19	3098-3101	IHC	abstract[151]|person	giv[151]|new	_	_
25-20	3102-3103	.	_	_	_	_

#Text=In this respect , important harmonization efforts have been made to standardize both the preanalytical and interpretative phases of PD-L1 testing , at least in non-small cell lung cancer ( NSCLC ) .
26-1	3104-3106	In	_	_	_	_
26-2	3107-3111	this	abstract[153]	new[153]	_	_
26-3	3112-3119	respect	abstract[153]	new[153]	_	_
26-4	3120-3121	,	_	_	_	_
26-5	3122-3131	important	abstract[155]	new[155]	_	_
26-6	3132-3145	harmonization	abstract|abstract[155]	new|new[155]	_	_
26-7	3146-3153	efforts	abstract[155]	new[155]	_	_
26-8	3154-3158	have	_	_	_	_
26-9	3159-3163	been	_	_	_	_
26-10	3164-3168	made	_	_	_	_
26-11	3169-3171	to	_	_	_	_
26-12	3172-3183	standardize	_	_	_	_
26-13	3184-3188	both	abstract[156]	new[156]	_	_
26-14	3189-3192	the	abstract[156]	new[156]	_	_
26-15	3193-3206	preanalytical	abstract[156]	new[156]	_	_
26-16	3207-3210	and	abstract[156]	new[156]	_	_
26-17	3211-3225	interpretative	abstract[156]	new[156]	_	_
26-18	3226-3232	phases	abstract[156]	new[156]	_	_
26-19	3233-3235	of	abstract[156]	new[156]	_	_
26-20	3236-3241	PD-L1	abstract[156]|abstract|abstract[158]	new[156]|giv|new[158]	coref|coref|coref|coref	27-4|27-4[165_158]|27-4|27-4[165_158]
26-21	3242-3249	testing	abstract[156]|abstract[158]	new[156]|new[158]	_	_
26-22	3250-3251	,	_	_	_	_
26-23	3252-3254	at	abstract[161]	new[161]	coref	29-14[181_161]
26-24	3255-3260	least	abstract[161]	new[161]	_	_
26-25	3261-3263	in	abstract[161]	new[161]	_	_
26-26	3264-3273	non-small	abstract[161]	new[161]	_	_
26-27	3274-3278	cell	place|abstract[161]	new|new[161]	coref	33-12
26-28	3279-3283	lung	object|abstract[161]	new|new[161]	_	_
26-29	3284-3290	cancer	abstract[161]	new[161]	_	_
26-30	3291-3292	(	_	_	_	_
26-31	3293-3298	NSCLC	organization	new	_	_
26-32	3299-3300	)	_	_	_	_
26-33	3301-3302	.	_	_	_	_

#Text=The reproducibility of PD-L1 testing in real-life clinical practice evaluated both for “ closed ” and “ open ” platforms , showed overlapping results , particularly when the 22C3 antibody clone was used .
27-1	3303-3306	The	abstract[163]	new[163]	_	_
27-2	3307-3322	reproducibility	abstract[163]	new[163]	_	_
27-3	3323-3325	of	abstract[163]	new[163]	_	_
27-4	3326-3331	PD-L1	abstract[163]|object|abstract[165]	new[163]|giv|giv[165]	_	_
27-5	3332-3339	testing	abstract[163]|abstract[165]	new[163]|giv[165]	_	_
27-6	3340-3342	in	abstract[163]|abstract[165]	new[163]|giv[165]	_	_
27-7	3343-3352	real-life	abstract[163]|abstract[165]|abstract[166]	new[163]|giv[165]|giv[166]	ana	27-11[167_166]
27-8	3353-3361	clinical	abstract[163]|abstract[165]|abstract[166]	new[163]|giv[165]|giv[166]	_	_
27-9	3362-3370	practice	abstract[163]|abstract[165]|abstract[166]	new[163]|giv[165]|giv[166]	_	_
27-10	3371-3380	evaluated	_	_	_	_
27-11	3381-3385	both	abstract[167]	giv[167]	_	_
27-12	3386-3389	for	abstract[167]	giv[167]	_	_
27-13	3390-3391	“	abstract[167]	giv[167]	_	_
27-14	3392-3398	closed	abstract[167]	giv[167]	_	_
27-15	3399-3400	”	abstract[167]	giv[167]	_	_
27-16	3401-3404	and	abstract[167]	giv[167]	_	_
27-17	3405-3406	“	abstract[167]|abstract[168]	giv[167]|new[168]	_	_
27-18	3407-3411	open	abstract[167]|abstract[168]	giv[167]|new[168]	_	_
27-19	3412-3413	”	abstract[167]|abstract[168]	giv[167]|new[168]	_	_
27-20	3414-3423	platforms	abstract[167]|abstract[168]	giv[167]|new[168]	_	_
27-21	3424-3425	,	_	_	_	_
27-22	3426-3432	showed	_	_	_	_
27-23	3433-3444	overlapping	abstract[169]	new[169]	_	_
27-24	3445-3452	results	abstract[169]	new[169]	_	_
27-25	3453-3454	,	_	_	_	_
27-26	3455-3467	particularly	_	_	_	_
27-27	3468-3472	when	_	_	_	_
27-28	3473-3476	the	object[171]	new[171]	_	_
27-29	3477-3481	22C3	object[171]	new[171]	_	_
27-30	3482-3490	antibody	substance|object[171]	new|new[171]	_	_
27-31	3491-3496	clone	object[171]	new[171]	_	_
27-32	3497-3500	was	_	_	_	_
27-33	3501-3505	used	_	_	_	_
27-34	3506-3507	.	_	_	_	_

#Text=On the other hand , there are several clues to advise that the same interpretation guidelines should not be translated across different tumor types .
28-1	3508-3510	On	_	_	_	_
28-2	3511-3514	the	_	_	_	_
28-3	3515-3520	other	_	_	_	_
28-4	3521-3525	hand	_	_	_	_
28-5	3526-3527	,	_	_	_	_
28-6	3528-3533	there	_	_	_	_
28-7	3534-3537	are	_	_	_	_
28-8	3538-3545	several	abstract[172]	new[172]	_	_
28-9	3546-3551	clues	abstract[172]	new[172]	_	_
28-10	3552-3554	to	_	_	_	_
28-11	3555-3561	advise	_	_	_	_
28-12	3562-3566	that	_	_	_	_
28-13	3567-3570	the	abstract[174]	giv[174]	_	_
28-14	3571-3575	same	abstract[174]	giv[174]	_	_
28-15	3576-3590	interpretation	abstract|abstract[174]	new|giv[174]	_	_
28-16	3591-3601	guidelines	abstract[174]	giv[174]	_	_
28-17	3602-3608	should	_	_	_	_
28-18	3609-3612	not	_	_	_	_
28-19	3613-3615	be	_	_	_	_
28-20	3616-3626	translated	_	_	_	_
28-21	3627-3633	across	_	_	_	_
28-22	3634-3643	different	place[176]	giv[176]	_	_
28-23	3644-3649	tumor	abstract|place[176]	giv|giv[176]	coref	29-5
28-24	3650-3655	types	place[176]	giv[176]	_	_
28-25	3656-3657	.	_	_	_	_

#Text=For example , the tumor proportion score ( TPS ) works perfectly for lung cancer but not for head and neck cancer , where the combined positive score ( CPS ) is more reliable .
29-1	3658-3661	For	_	_	_	_
29-2	3662-3669	example	_	_	_	_
29-3	3670-3671	,	_	_	_	_
29-4	3672-3675	the	abstract[179]	new[179]	appos	29-9[0_179]
29-5	3676-3681	tumor	abstract|abstract[179]	giv|new[179]	coref	30-33
29-6	3682-3692	proportion	abstract|abstract[179]	new|new[179]	_	_
29-7	3693-3698	score	abstract[179]	new[179]	_	_
29-8	3699-3700	(	_	_	_	_
29-9	3701-3704	TPS	abstract	giv	coref	29-25[185_0]
29-10	3705-3706	)	_	_	_	_
29-11	3707-3712	works	_	_	_	_
29-12	3713-3722	perfectly	_	_	_	_
29-13	3723-3726	for	_	_	_	_
29-14	3727-3731	lung	abstract[181]	giv[181]	coref	29-21[184_181]
29-15	3732-3738	cancer	abstract[181]	giv[181]	_	_
29-16	3739-3742	but	_	_	_	_
29-17	3743-3746	not	_	_	_	_
29-18	3747-3750	for	_	_	_	_
29-19	3751-3755	head	object	new	_	_
29-20	3756-3759	and	_	_	_	_
29-21	3760-3764	neck	object|abstract[184]	new|giv[184]	_	_
29-22	3765-3771	cancer	abstract[184]	giv[184]	_	_
29-23	3772-3773	,	_	_	_	_
29-24	3774-3779	where	_	_	_	_
29-25	3780-3783	the	abstract[185]	giv[185]	coref	31-12[199_185]
29-26	3784-3792	combined	abstract[185]	giv[185]	_	_
29-27	3793-3801	positive	abstract[185]	giv[185]	_	_
29-28	3802-3807	score	abstract[185]	giv[185]	_	_
29-29	3808-3809	(	_	_	_	_
29-30	3810-3813	CPS	object	new	coref	31-2[196_0]
29-31	3814-3815	)	_	_	_	_
29-32	3816-3818	is	_	_	_	_
29-33	3819-3823	more	_	_	_	_
29-34	3824-3832	reliable	_	_	_	_
29-35	3833-3834	.	_	_	_	_

#Text=These two scoring systems are rather different , given that the former considers only the percentage of PD-L1-positive neoplastic cells , while the latter combines all PD-L1-positive cells ( i. e. , tumor cells , lymphocytes , and macrophages ) into the following formula .
30-1	3835-3840	These	abstract[187]	new[187]	_	_
30-2	3841-3844	two	abstract[187]	new[187]	_	_
30-3	3845-3852	scoring	abstract[187]	new[187]	_	_
30-4	3853-3860	systems	abstract[187]	new[187]	_	_
30-5	3861-3864	are	_	_	_	_
30-6	3865-3871	rather	_	_	_	_
30-7	3872-3881	different	_	_	_	_
30-8	3882-3883	,	_	_	_	_
30-9	3884-3889	given	_	_	_	_
30-10	3890-3894	that	_	_	_	_
30-11	3895-3898	the	_	_	_	_
30-12	3899-3905	former	_	_	_	_
30-13	3906-3915	considers	_	_	_	_
30-14	3916-3920	only	quantity[188]	new[188]	_	_
30-15	3921-3924	the	quantity[188]	new[188]	_	_
30-16	3925-3935	percentage	quantity[188]	new[188]	_	_
30-17	3936-3938	of	quantity[188]	new[188]	_	_
30-18	3939-3953	PD-L1-positive	quantity[188]|object[189]	new[188]|new[189]	coref	30-26[190_189]
30-19	3954-3964	neoplastic	quantity[188]|object[189]	new[188]|new[189]	_	_
30-20	3965-3970	cells	quantity[188]|object[189]	new[188]|new[189]	_	_
30-21	3971-3972	,	_	_	_	_
30-22	3973-3978	while	_	_	_	_
30-23	3979-3982	the	_	_	_	_
30-24	3983-3989	latter	_	_	_	_
30-25	3990-3998	combines	_	_	_	_
30-26	3999-4002	all	object[190]	giv[190]	coref	30-33[192_190]
30-27	4003-4017	PD-L1-positive	object[190]	giv[190]	_	_
30-28	4018-4023	cells	object[190]	giv[190]	_	_
30-29	4024-4025	(	_	_	_	_
30-30	4026-4028	i.	_	_	_	_
30-31	4029-4031	e.	_	_	_	_
30-32	4032-4033	,	_	_	_	_
30-33	4034-4039	tumor	abstract|object[192]	giv|giv[192]	appos|coref|appos|coref	30-36[0_192]|33-21|30-36[0_192]|33-21
30-34	4040-4045	cells	object[192]	giv[192]	_	_
30-35	4046-4047	,	_	_	_	_
30-36	4048-4059	lymphocytes	abstract	giv	appos	30-39[194_0]
30-37	4060-4061	,	_	_	_	_
30-38	4062-4065	and	_	_	_	_
30-39	4066-4077	macrophages	object[194]	giv[194]	coref	34-13[218_194]
30-40	4078-4079	)	object[194]	giv[194]	_	_
30-41	4080-4084	into	object[194]	giv[194]	_	_
30-42	4085-4088	the	object[194]|abstract[195]	giv[194]|new[195]	_	_
30-43	4089-4098	following	object[194]|abstract[195]	giv[194]|new[195]	_	_
30-44	4099-4106	formula	object[194]|abstract[195]	giv[194]|new[195]	_	_
30-45	4107-4108	.	_	_	_	_

#Text=Although the CPS can theoretically exceed the value of 100 , the maximum score is defined as 100 .
31-1	4109-4117	Although	_	_	_	_
31-2	4118-4121	the	object[196]	giv[196]	_	_
31-3	4122-4125	CPS	object[196]	giv[196]	_	_
31-4	4126-4129	can	_	_	_	_
31-5	4130-4143	theoretically	_	_	_	_
31-6	4144-4150	exceed	_	_	_	_
31-7	4151-4154	the	abstract[197]	giv[197]	_	_
31-8	4155-4160	value	abstract[197]	giv[197]	_	_
31-9	4161-4163	of	abstract[197]	giv[197]	_	_
31-10	4164-4167	100	abstract[197]|quantity	giv[197]|new	coref	31-18
31-11	4168-4169	,	_	_	_	_
31-12	4170-4173	the	abstract[199]	giv[199]	_	_
31-13	4174-4181	maximum	abstract[199]	giv[199]	_	_
31-14	4182-4187	score	abstract[199]	giv[199]	_	_
31-15	4188-4190	is	_	_	_	_
31-16	4191-4198	defined	_	_	_	_
31-17	4199-4201	as	_	_	_	_
31-18	4202-4205	100	quantity	giv	_	_
31-19	4206-4207	.	_	_	_	_

#Text=Fascinating perspectives are being provided by experimental models addressing the plasticity of the cellular inflammatory response of the host .
32-1	4208-4219	Fascinating	abstract[201]	new[201]	_	_
32-2	4220-4232	perspectives	abstract[201]	new[201]	_	_
32-3	4233-4236	are	_	_	_	_
32-4	4237-4242	being	_	_	_	_
32-5	4243-4251	provided	_	_	_	_
32-6	4252-4254	by	_	_	_	_
32-7	4255-4267	experimental	abstract[202]	new[202]	_	_
32-8	4268-4274	models	abstract[202]	new[202]	_	_
32-9	4275-4285	addressing	_	_	_	_
32-10	4286-4289	the	abstract[203]	new[203]	_	_
32-11	4290-4300	plasticity	abstract[203]	new[203]	_	_
32-12	4301-4303	of	abstract[203]	new[203]	_	_
32-13	4304-4307	the	abstract[203]|abstract[204]	new[203]|giv[204]	_	_
32-14	4308-4316	cellular	abstract[203]|abstract[204]	new[203]|giv[204]	_	_
32-15	4317-4329	inflammatory	abstract[203]|abstract[204]	new[203]|giv[204]	_	_
32-16	4330-4338	response	abstract[203]|abstract[204]	new[203]|giv[204]	_	_
32-17	4339-4341	of	abstract[203]|abstract[204]	new[203]|giv[204]	_	_
32-18	4342-4345	the	abstract[203]|abstract[204]|person[205]	new[203]|giv[204]|new[205]	_	_
32-19	4346-4350	host	abstract[203]|abstract[204]|person[205]	new[203]|giv[204]|new[205]	_	_
32-20	4351-4352	.	_	_	_	_

#Text=There are several lines of evidence to suggest that the myeloid-derived cell function is a finely tuned mechanism to control tumor growth .
33-1	4353-4358	There	_	_	_	_
33-2	4359-4362	are	_	_	_	_
33-3	4363-4370	several	abstract[206]	new[206]	_	_
33-4	4371-4376	lines	abstract[206]	new[206]	_	_
33-5	4377-4379	of	abstract[206]	new[206]	_	_
33-6	4380-4388	evidence	abstract[206]|abstract	new[206]|new	_	_
33-7	4389-4391	to	_	_	_	_
33-8	4392-4399	suggest	_	_	_	_
33-9	4400-4404	that	_	_	_	_
33-10	4405-4408	the	abstract[209]	new[209]	coref	33-15[210_209]
33-11	4409-4424	myeloid-derived	abstract[209]	new[209]	_	_
33-12	4425-4429	cell	object|abstract[209]	giv|new[209]	_	_
33-13	4430-4438	function	abstract[209]	new[209]	_	_
33-14	4439-4441	is	_	_	_	_
33-15	4442-4443	a	abstract[210]	giv[210]	ana	34-10[0_210]
33-16	4444-4450	finely	abstract[210]	giv[210]	_	_
33-17	4451-4456	tuned	abstract[210]	giv[210]	_	_
33-18	4457-4466	mechanism	abstract[210]	giv[210]	_	_
33-19	4467-4469	to	_	_	_	_
33-20	4470-4477	control	_	_	_	_
33-21	4478-4483	tumor	abstract|abstract[212]	giv|new[212]	ana|coref|ana|coref	34-3[213_212]|34-14|34-3[213_212]|34-14
33-22	4484-4490	growth	abstract[212]	new[212]	_	_
33-23	4491-4492	.	_	_	_	_

#Text=Specifically , both in local and hematopoietic niches , its crosstalk with the tumor cells as well as with exogenous stimuli , is based on the microbiota repertoire .
34-1	4493-4505	Specifically	_	_	_	_
34-2	4506-4507	,	_	_	_	_
34-3	4508-4512	both	abstract[213]	giv[213]	_	_
34-4	4513-4515	in	abstract[213]	giv[213]	_	_
34-5	4516-4521	local	abstract[213]|place[214]	giv[213]|new[214]	_	_
34-6	4522-4525	and	abstract[213]|place[214]	giv[213]|new[214]	_	_
34-7	4526-4539	hematopoietic	abstract[213]|place[214]	giv[213]|new[214]	_	_
34-8	4540-4546	niches	abstract[213]|place[214]	giv[213]|new[214]	_	_
34-9	4547-4548	,	_	_	_	_
34-10	4549-4552	its	abstract|abstract[216]	giv|new[216]	_	_
34-11	4553-4562	crosstalk	abstract[216]	new[216]	_	_
34-12	4563-4567	with	abstract[216]	new[216]	_	_
34-13	4568-4571	the	abstract[216]|object[218]	new[216]|giv[218]	_	_
34-14	4572-4577	tumor	abstract[216]|abstract|object[218]	new[216]|giv|giv[218]	_	_
34-15	4578-4583	cells	abstract[216]|object[218]	new[216]|giv[218]	_	_
34-16	4584-4586	as	_	_	_	_
34-17	4587-4591	well	_	_	_	_
34-18	4592-4594	as	_	_	_	_
34-19	4595-4599	with	_	_	_	_
34-20	4600-4609	exogenous	abstract[219]	new[219]	_	_
34-21	4610-4617	stimuli	abstract[219]	new[219]	_	_
34-22	4618-4619	,	_	_	_	_
34-23	4620-4622	is	_	_	_	_
34-24	4623-4628	based	_	_	_	_
34-25	4629-4631	on	_	_	_	_
34-26	4632-4635	the	abstract[221]	giv[221]	_	_
34-27	4636-4646	microbiota	person|abstract[221]	new|giv[221]	_	_
34-28	4647-4657	repertoire	abstract[221]	giv[221]	_	_
34-29	4658-4659	.	_	_	_	_
